Engineered Endolysin and Yeast Delivery System for Targeted Control of Clostridium perfringens in Chickens
Engineered enzymes called endolysins are produced in yeast and mixed into chicken feed to kill Clostridium perfringens. This offers a promising antibiotic alternative for treating livestock infections and preventing food poisoning.
Background
The prevalence of bacterial infections in both human health and animal agriculture has heightened the need for targeted antimicrobial technologies. Over the years, traditional antibiotics have been the primary defense against harmful bacteria, yet their broad-spectrum nature often disrupts beneficial microbial communities. This situation is particularly critical in food safety and livestock management, where maintaining a balanced microbiome is essential. Moreover, the widespread use of antibiotics has led to growing concerns about diminishing efficacy and the emergence of antibiotic-resistant strains, underscoring the urgency for alternative, more precise antimicrobial strategies.
Current approaches to bacterial control face significant challenges, primarily due to their non-specific mechanisms of action. Conventional antibiotics not only target pathogenic bacteria but also adversely affect the beneficial microbes present in the gut or other environments, leading to imbalances that can compromise overall health. Additionally, the overuse of these agents in animal feed has contributed to an increased risk of resistance, which diminishes their effectiveness over time. These limitations highlight the pressing need to develop innovative solutions that can selectively combat harmful bacteria while preserving the delicate equilibrium of microbial ecosystems.
Technology
Four distinct proteins have been developed to target Clostridium perfringens by breaking down its protective cell wall. Each protein contains a catalytic domain specifically designed to degrade peptidoglycan; two use glycosyl hydrolase activity while the other two employ L-alanine amidase action. They were engineered from prophage genetic material and optimized for expression in bacterial cells, then further produced using a yeast expression system. These proteins effectively lyse a wide range of C. perfringens strains without harming other microbes, suggesting strong potential for medical or agricultural applications.
What sets this technology apart is its precision in combating a problematic bacterium while minimizing collateral damage often seen with conventional antibiotics. Their selective mechanism reduces the risk of resistance and ensures safety for beneficial bacteria. The ability to produce these proteins at scale using both bacterial and yeast systems, combined with robust testing in controlled and real-world environments, highlights a promising alternative to traditional antimicrobial strategies in both human health and livestock management.
Benefits
- Highly specific targeting of Clostridium perfringens without affecting other bacteria
- Effective alternative to conventional antibiotics, reducing the risk of antibiotic resistance
- Demonstrated efficacy in both in vitro and ex vivo models
- Potential application in controlling necrotic enteritis in livestock and food poisoning in humans
- Cost-effective production and delivery using a yeast expression system
- Compatible with current restrictions on antibiotic use in animal feed
Applications
- Livestock necrotic enteritis treatment
- Food safety enhancement
- Antibiotic alternative development
- Probiotic feed additives
- Human food poisoning prevention
Additional info
Four distinct endolysins—PlyCP10, PlyCP18, PlyCP33, and PlyCP41—target Clostridium perfringens cell walls using glycosyl hydrolase or L-alanine amidase domains. Their genes were codon-optimized, cloned into E. coli vectors with 6×His tags, and purified via nickel chromatography. These enzymes effectively lysed 66 C. perfringens strains without impacting other bacteria. Additionally, PlyCP41 expressed in Saccharomyces cerevisiae significantly reduced C. perfringens counts in both in vitro and ex vivo assays, presenting a viable alternative to traditional antibiotics.